Cargando…
The multigene classifiers 95GC/42GC/155GC for precision medicine in ER‐positive HER2‐negative early breast cancer
In clinical decision‐making, to decide the indication for adjuvant chemotherapy for estrogen receptor‐positive (ER+), human epidermal growth factor receptor‐2‐negative (HER2−), and node‐negative (n0) breast cancer patients, the accurate estimation of recurrence risk is essential. Unfortunately, conv...
Autores principales: | Naoi, Yasuto, Tsunashima, Ryo, Shimazu, Kenzo, Noguchi, Shinzaburo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8019222/ https://www.ncbi.nlm.nih.gov/pubmed/33544932 http://dx.doi.org/10.1111/cas.14838 |
Ejemplares similares
-
Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative invasive breast cancer classified as low risk by Curebest(™) 95GC Breast in a multi‑institutional registry study
por: Naoi, Yasuto, et al.
Publicado: (2023) -
Functions of NO-GC1 and NO-GC2 in pain processing
por: Petersen, Jonas, et al.
Publicado: (2015) -
Global Urinary
Volatolomics with (GC×)GC-TOF-MS
por: Myridakis, Antonis, et al.
Publicado: (2023) -
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
por: Hori, Ami, et al.
Publicado: (2019) -
Endocrine sensitivity of estrogen receptor‐positive breast cancer is negatively correlated with aspartate‐β‐hydroxylase expression
por: Shimoda, Masafumi, et al.
Publicado: (2017)